Gyre Therapeutics shares surge 11.58% intraday after Q3 earnings beat with revenue growth and clinical trial updates.

Gyre Therapeutics surged 11.58% intraday after reporting strong Q3 2025 results, including $30.6 million in revenue (20% YoY growth) driven by $27.7 million in Etuary sales, and $5.9 million in net income. The company also advanced multiple clinical programs, completing enrollment in a Phase 3 trial for Etuary in pneumonoconiosis and progressing toward an NDA submission for Hydronidone in China. These developments, combined with a robust cash balance of $80.3 million, signaled operational and financial momentum, likely driving the significant intraday price increase.